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Abstract 31 
Context: Measuring serum cortisol to evaluate stress, adrenal disease, and monitor 32 
hydrocortisone replacement requires venepuncture. Conversely, salivary measurements are 33 
non-invasive.  34 
Objective: To investigate measurement of salivary cortisol and cortisone as alternatives to 35 
serum cortisol. 36 
Design & Setting: A prospective cross-over study in a Clinical Research Facility. 37 
Participants & method: Over 3 periods (period 1: 24h physiological cortisol rhythm; 38 
periods 2 and 3: after 20mg oral and intravenous hydrocortisone) 14 male volunteers had 39 
serum and saliva cortisol and cortisone, serum albumin, CBG, and free cortisol measured. 40 
Data were analysed for rhythm parameters and correlations. Linear mixed effects modelling 41 
was performed to determine the relationship between serum cortisol and salivary cortisone.  42 
Results: Serum cortisol and cortisone showed similar circadian rhythms with large 43 
peak:trough ratios (cortisol median ratio 11). Albumin and CBG showed minor peak:trough 44 
ratios <1.2. When serum cortisol was <74 (SD 29) nmol/L, salivary cortisol was not 45 
detectable but salivary cortisone was always detected. Salivary cortisol post-oral 46 
hydrocortisone produced spurious results due to contamination. Under physiological 47 
conditions, salivary cRUWLVRQHFRUUHODWHGVWURQJO\ZLWKVHUXPFRUWLVRO>ȡ&,-48 
0.93);P<0.001]. Similarly, following intravenous or oral hydrocortisone, salivary cortisone 49 
correlated strongly with serum coUWLVRO>ȡ&, -0.92); P<0.001]. A mixed 50 
effects model showed that in this population 94% of the variation in salivary cortisone could 51 
be predicted from serum cortisol. 52 
Conclusion: Salivary cortisol is frequently undetectable and contaminated by oral 53 
hydrocortisone. In contrast, salivary cortisone reflects serum cortisol and provides a non-54 
invasive alternative to measuring serum cortisol levels. 55 
56 
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Introduction 57 
Cortisol measurement is important in the assessment of adrenal function and also used for 58 
assessing the adequacy of hydrocortisone replacement and as a marker of stress in studies of 59 
human behaviour. Cortisol levels have a distinct circadian rhythm being low in the evening 60 
and at sleep onset, rising from around 0300h-0500h, peaking shortly after waking and then 61 
declining over the day with small peaks at meal times (1,2). Therefore the timing of cortisol 62 
samples is very important when assessing cortisol exposure; for example a midnight cortisol 63 
is used WR GLDJQRVH &XVKLQJ¶V V\QGURPH (3), an early morning cortisol measurement to 64 
examine for adrenal insufficiency and some clinicians use multiple cortisol samples when 65 
assessing hydrocortisone replacement therapy (4). The measurement of serum cortisol is 66 
inconvenient and expensive involving venepuncture and either a visit to the clinic or hospital 67 
admission. In contrast, the measurement of salivary cortisol is relatively non-invasive and 68 
convenient for the patient as it can be done at home and posted to the laboratory (5). The 69 
measurement of salivary cortisol however, has limitations as it is undetectable at low levels 70 
of serum cortisol (6), and oral hydrocortisone contaminates the mouth resulting in spuriously 71 
high salivary cortisol levels (7).  72 
 73 
It is important to consider the transport of cortisol in the circulation when measuring serum 74 
cortisol; 80% is bound to cortisol binding globulin (CBG), 10% to albumin and 75 
approximately 10% is free cortisol (unbound fraction), the latter providing biological activity 76 
(8). As cortisol concentration exceeds ~550nmol/L CBG saturates so that the biologically 77 
active free cortisol increases. At these levels the clearance of total cortisol increases (9), and 78 
the disappearance rate is negatively correlated with CBG (10). CBG has a diurnal rhythm in 79 
rats (11), and the metabolic clearance rate of cortisol in humans is significantly higher at 80 
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0500h to 1100h compared to that at 2000h to 0200h (12). Salivary cortisol has been shown to 81 
reflect serum free cortisol (7). 82 
 83 
The enzyme 11ȕ-hydroxysteroid dehydrogenase type 2 (11ȕ-HSD2) is expressed in the 84 
salivary glands and rapidly inactivates cortisol by conversion to cortisone (13). In serum, 85 
levels of cortisone are approximately 4-fold less than those of cortisol whereas in saliva 86 
levels of cortisone are approximately 6-fold higher than those of cortisol and presumed to be 87 
generated during the production of saliva from free serum cortisol (6). Thus, salivary 88 
cortisone predominantly reflects serum free cortisol.   89 
 90 
Cortisone is present at higher concentration than cortisol in saliva and has previously been 91 
shown to have a linear relationship with serum cortisol and therefore has the potential to 92 
provide a good marker of serum cortisol (14). We propose that the measurement of salivary 93 
cortisone can be used to estimate serum cortisol and serum free cortisol and to test this we 94 
examined the relationship between serum cortisol, cortisone, free cortisol and salivary 95 
cortisol and cortisone under physiological conditions and after the administration of 96 
hydrocortisone orally and intravenously. 97 
 98 
Methods and subjects 99 
A single centre, prospective, cross over study was carried out at Simbec Research Limited 100 
Clinical Centre. Fourteen healthy male volunteers with a median (IQR) age of 28 (25 ± 36) 101 
years, weight 83 (75 ± 90) kg and BMI 25.3 (23.1 ± 26.3) kg/m2 participated in the study. 102 
Inclusion criteria included ages 18 to 60 years of age, a BMI of 21 to 28 kg/m2, and no 103 
clinically significant liver, renal or cardiac disease. Exclusion criteria were the presence of 104 
gastrointestinal disorders that could influence drug absorption; renal, hepatic, central nervous 105 
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system, respiratory, cardiovascular or metabolic dysfunction, drug or alcoholic abuse, 106 
presence of infections, regular medications 14 days prior to study start, use of 107 
glucocorticoids, smokers and rotating work shifts. None of the subjects had diabetes or other 108 
significant comorbidities. The study was approved by the South East Wales Research Ethics 109 
Committee and all participants gave written informed consent. The study was divided into 110 
three study periods:  111 
 112 
Study period 1, Physiological Circadian Cortisol rhythm: Volunteers were admitted to the 113 
Clinical Centre and serum and saliva sampling was commenced at 1500h on Day 1 under 114 
stable conditions. Standard mixed meals were given on Day 1 at 1300h and 1900h and on 115 
Day 2 at 0800h and 1300h. Sleep disruption was minimised and subjects slept with lights out 116 
from 2300h to 0600h. Serum samples for circulating cortisol and cortisone, cortisol binding 117 
globulin and albumin were collected every hour until Day 2 at 1500h whereas salivary 118 
samples for cortisol and cortisone were collected every hour between 1500h and 2200h and 119 
between 0700h and 1500h. Subjects were asked not to eat, drink or wash their teeth 30 120 
minutes prior to each sample collected. Serum free cortisol was measured at 2200h, 0700h 121 
and 0900h.    122 
 123 
Study periods 2 & 3, oral and intravenous (IV) hydrocortisone administration: During 124 
period 2 each volunteer was administered 20mg oral hydrocortisone and during period 3 125 
20mg IV at 07:00h. Serum samples for cortisol, cortisone, cortisol binding globulin and 126 
albumin and salivary samples for cortisol and cortisone were taken at -10min, 15min, 30min, 127 
45min, 60min, 1 hr 15min, 1 hr 30min, 2hr, 2hr 30min, 3hr, 4hr, 5hr, 6hr, 8hr, 10hr and 12hr. 128 
Free cortisol levels were measured at -10min and at 2 hours post drug administration. 129 
Volunteers received dexamethasone 1mg orally at ~2200h on Day 1 and at ~0600h and 130 
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~1200h on Day 2 during each study period to suppress the hypothalamo-pituitary-adrenal 131 
axis. All volunteers were given a standard mixed meal on Day 1 at 1900h and on Day 2 at 132 
0800h and 1300h.  133 
 134 
Assays: LC-MS/MS analysis for serum, free and salivary cortisol/cortisone was performed  135 
using a Waters Xevo TQ-MSTM mass spectrometer and a Waters AcquityTM  LC system with 136 
an electrospray source operated in positive ionisation mode (15). The lower limit of 137 
quantitation (LLOQ) for serum cortisol was was 12.5nmol/L. The inter-assay imprecision 138 
was 8, 7 and 6% at concentrations of 80, 480 and 842nmol/L respectively.  The cumulative 139 
intra-assay and inter-assay coefficients of variation (CVs) for the LC-MS/MS method for free 140 
cortisol were <8% and <9.5% respectively. Salivary cortisol and cortisone were measured 141 
with a modified LC-MS/MS assay with lower limits of detection 0.80nmol/L (salivary 142 
cortisol) and 0.50nmol/L (salivary cortisone). Intrassay CVs were less than 9.3% and less 143 
than 7.9%; and interassay CVs were less than 9.7% and less than 10.3% at 1.8±52.2 nmol/L 144 
of salivary cortisol and 3.6±96 nmol/L of salivary cortisone, respectively (16). Free cortisol 145 
was measured using the same method as saliva but serum samples were filtered with a 146 
molecular weight centrifugal filter (cut off 30,000Da) prior to analysis to remove binding 147 
proteins. Inter assay CVs were less than 8% at 40-85 nmol/L of free cortisol.  148 
 149 
Statistical Analysis: All statistical analyses were performed using MatLab and Microsoft 150 
Excel 2010. Means or medians and 95% confidence intervals (CI), inter-quartile ranges or 151 
ranges were calculated for continuous variables.  The free cortisol index (FCI) was calculated 152 
as serum total cortisol/CBG (nmol/mg). The peak-to-trough ratio was estimated by the 153 
maximal concentration/minimal concentration of the substrate over 24 hours. The serum free 154 
cortisol (FF) was expressed as a percentage of total serum cortisol (SF): (FF/SF*100%). The 155 
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difference in FF/SF*100% between separate time points was assessed using non-parametric 156 
Wilcoxon test for related samples. Linear mixed effects models were used for both cosinor 157 
and regression analysis to account for intra- and inter-subject variability. Model selection was 158 
by likelihood-ratio test between models and statistically significant but more complex models 159 
with only marginal improvement in Akaike Information Criterion (AIC) or Bayesian 160 
Information Criterion (BIC) were rejected in favour of simplicity. The selected mixed effects 161 
models were all found to be superior to their fixed effects equivalents (P<=0.001) although 162 
only marginally so for the cosinor models of albumin and CBG. 163 
 164 
Results 165 
During physiological conditions (study period 1), serum cortisol, cortisone and the 166 
calculated free cortisol index [FCI; serum total cortisol/CBG (nmol/mg)] all showed a similar 167 
circadian rhythm as defined by a cosinor model, with similar times for acrophase and nadir 168 
and similar peak to trough ratios (Table 1; Fig.1). The peak to trough ratios were large in 169 
amplitude for both serum cortisol and cortisone; median (range) 11.05 (6.57-66.77) and 6.16 170 
(3.37-15.24), respectively. Serum CBG and albumin showed a statistically significant but 171 
very low amplitude circadian rhythm, the acrophase at around 1600h to 1700h was out of 172 
phase with serum cortisol, and the peak to trough ratios for CBG and albumin were small at 173 
<1.2. Serum cortisol, FCI and free cortisol showed similar changes over the day being high 174 
first thing in the morning and low at night. Serum free cortisol when expressed as a 175 
percentage of total serum cortisol (FF/SF*100) was lower in the evening when compared to 176 
morning (Supp Table 1).  177 
 178 
There was considerable individual variability in the serum cortisol:cortisone ratio, however 179 
there was a circadian rhythm (p<001): the median (range) mesor was 4.3 (3.0 ² 5.8) 180 
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peak:trough ratio 1.4 (1.3 ± 1.5), peak 5.0  (3.7 ² 6.6), trough 3.6 (2.4 ² 5.0), acrophase 181 
08:08h (07:17±08:51h), and nadir 20:04h (19:13 ± 20:47h) (Supp Fig. 1a). Individual cross-182 
correlation analysis of serum cortisol with serum cortisone for relative shifts from -24 to 24 183 
hours showed a clear maximum at zero (P<0.001) for all subjects (Supp Fig. 1). This 184 
suggests that whilst the changes in cortisone concentrations might lag cortisol, any such lag is 185 
undetectable at the one hour resolution of the data. 186 
 187 
 &, IRU FRUUHODWLRQV ȡ RI VDOLYDU\ FRUWLVRQH DQG VDOLYDU\ FRUWLVRO ZLWK VHUXP FRUWLVRO188 
rhythm varied between 0.89 - 0.93 and from 0.86 - 0.92; P<0.001, respectively. When serum 189 
cortisol was <74 (SD 29) nmol/L, salivary cortisol was not detectable (19% of total values). 190 
After excluding these undetectable values salivary cortisol and cortisone both showed very 191 
strong correlations with serum cortisol, cortisone, FCI, and free cortisol (Table 2). The 192 
strongest correlation was between salivary cortisone and serum cortisol. The median (range) 193 
ratio between salivary cortisone and salivary cortisol was 6.4 (Range 2.4 - 14.6). 194 
 195 
Study periods 2 & 3, following oral and IV administration of hydrocortisone: After oral 196 
hydrocortisone administration salivary cortisol levels showed no correlation with serum 197 
cortisol (Table 3a). This was related to some salivary cortisol values showing spuriously high 198 
levels presumed to be contamination from the oral hydrocortisone which was not seen after 199 
intravenous. By contrast, salivary cortisone maintained a strong correlation with serum 200 
cortisol, and FCI and the correlation coefficient for salivary cortisone with serum cortisol was 201 
the same DVWKDWVHHQXQGHUSK\VLRORJLFDOFRQGLWLRQVȡ P<0.001) (Table 3b).  202 
 203 
Pooling data from periods 1, 2 & 3: there was a strong linear relationship between salivary 204 
cortisone and serum cortisol (Fig. 2a). Logarithmic transformation reduced heteroscedasticity 205 
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in the variance and was used in a linear mixed effects model grouped by subject (Fig. 2b). 206 
The best fit model required only random intercepts for each subject (likelihood ratio test, 207 
P<=0.001) and explained 94% of the variability in the data. The explanation for the inter-208 
subject variability was further explored by examining age, body mass index (BMI), body 209 
surface area (BSA), height, and weight however none of these variables could contribute 210 
significantly to the model. The final, best-fit model is given by log10 serum F = 1.24 + 0.89 × 211 
log10 salivary E + bj, where bj represents the modification of the intercept for subject j, j = 212 
«DQGYDOXHVUDQJHGIURP-0.13 to 0.14. 213 
 214 
Normative salivary cortisol and cortisone levels: To calculate the 24 hour rhythm of 215 
salivary cortisol and salivary cortisone we used the fixed-effects components of the fitted 216 
UHJUHVVLRQ PRGHOV WR ³EDFN WUDQVIRUP´ WKH -cosinor model for serum cortisol. The full, 217 
mixed effects regressions were also used to provide estimates of the missing night-time 218 
salivary cortisone levels (2300h to 0600h) (Fig. 3). 219 
 220 
Discussion 221 
Salivary cortisol and salivary cortisone show a very strong correlation to serum cortisol and 222 
salivary cortisone provides a better marker of serum cortisol as it is detectable at low levels of 223 
serum cortisol and not contaminated by oral hydrocortisone. We found that CBG and albumin 224 
showed a circadian rhythm that was out of phase with the circadian rhythm of cortisol. 225 
However, the peak to trough ratio for both CBG and albumen was <1.2 and therefore the 226 
circadian changes in serum cortisol and serum free cortisol within an individual over 24h is 227 
predominantly due to either secretion of cortisol or absorption of hydrocortisone with 228 
changes in CBG and albumen having a minimal effect. Salivary cortisone has previously 229 
been shown to have a linear relationship to serum cortisol (6,14). We have now extended this 230 
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observation by modelling the relationship in fine detail over 24 hours, confirming it exists 231 
under both physiological cortisol secretion and after the administration of hydrocortisone, and 232 
by defining the key parameters of salivary cortisone levels over 24 hours. 233 
 234 
Cortisol is inactivated through oxidation to cortisone E\ȕ-HSD Type 2 in organs such as 235 
kidney, salivary glands and the colon and cortisone is either excreted in urine or re-shuttled 236 
EDFN LQWR WKHFLUFXODWLRQ WREH UHGXFHGEDFN WR FRUWLVROE\ȕ-HSD Type 1 in the tissues 237 
(17,18). By activating cortisone to cortisol, the Type 1 enzyme amplifies the effect of cortisol 238 
in tissues, including liver and adipose tissue (19). Our results showed that serum cortisone 239 
correlated strongly with serum cortisol. Cross correlation analysis showed correlation 240 
between serum cortisol and simultaneously measured cortisone suggesting that both under 241 
physiological conditions and after administration of hydrocortisone there is rapid conversion 242 
of serum cortisol to serum cortisone, at least within the sampling period of the study. This 243 
conversion of cortisol to cortisone predominantly reflects WKHIXQFWLRQRIȕ-HSD Type 2 in 244 
the kidneys as it protects the mineralocorticoid receptor from excess active cortisol by 245 
converting it to inactive cortisone (20). From our results serum cortisol levels exceed those of 246 
cortisone with a ratio of 4.3 cortisol:cortisone. In contrast in saliva cortisone levels exceed 247 
those of cortisol with a ratio of 6.4 cortisone:cortisol. There was considerable individual 248 
variability in the serum cortisol:cortisone ratio, however there was a low amplitude circadian 249 
rhythm with a mesor of 4.3. Previous publications have demonstrated that salivary cortisone 250 
closely reflects serum free cortisol (6,14). We have now shown that both salivary cortisol and 251 
cortisone have a much stronger correlation with serum cortisol than with serum cortisone 252 
consistent with salivary cortisone being derived from serum free cortisol through conversion 253 
E\ȕ-HSD Type 2 in the salivary gland. We have established that repetitive sampling of 254 
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salivary cortisone is a suitable alternative to measuring serum cortisol both under 255 
physiological conditions and after the administration of hydrocortisone.     256 
 257 
We further examined the relationship between salivary cortisone and serum cortisol using a 258 
mixed effects model. Log transforming the data provided a minor improvement in the model 259 
and reduced the heteroscedasticity in the residuals. In this population around 94% of the 260 
variability in salivary cortisone could be explained by the change in serum cortisol. We 261 
examined demographic characteristics (age, weight, height, BMI, BSA) to see if they 262 
explained the minor inter-subject variability but they were found not to do so. We would 263 
therefore propose a fixed effects model could be used to back calculate serum cortisol from 264 
salivary cortisone but this needs to be tested in prospective studies in different populations. 265 
By inverting the mixed effects model to estimate night-time salivary cortisone levels, we 266 
developed a full 24-hour salivary cortisone rhythm model (Fig. 3), and this could be used in 267 
clinical practice. 268 
 269 
The use of salivary methods to measure cortisol is becoming increasingly common both in 270 
research and in the clinical management of patients as an alternative, or an adjunct, to the 271 
more frequently used serum or urinary cortisol measurements. The introduction of LC-272 
MS/MS has further increased the sensitivity and specificity of the assays and allows the 273 
simultaneous measurement of both salivary cortisol and cortisone (6). Immunoassays are 274 
complicated by cross-reactivity with other steroids including cortisone, which impacts on 275 
specificity and test accuracy (21). The use of LC-MS/MS as in this study is important for the 276 
individual measurement of steroids, including cortisol and cortisone. The methods used are 277 
becoming simpler, faster and have a quick turn-around achieving speeds similar to 278 
immunoassays. They are therefore used extensively in hospital laboratories (22), are an ideal 279 
12 
 
tool for researchers and the measurement of salivary cortisol has been recommended in major 280 
guidelines (3).  However, despite the improved sensitivity of LC-MS/MS we were still unable 281 
to measure salivary cortisol when the serum cortisol was low. 282 
 283 
Disturbances in cortisol rhythm are associated with ill-health. A flattened diurnal cortisol 284 
slope is associated with cardiovascular mortality (23), Type 2 diabetes (24) and obesity (25). 285 
Therefore, measuring the cortisol rhythm by stress free, non-invasive salivary cortisone 286 
sampling could potentially be an additional means of assessing patient health risk on an 287 
everyday basis; though this still needs to be established in future studies. Furthermore, no 288 
consensus exists on how to titrate hydrocortisone doses in patients on glucocorticoid 289 
replacement (26). The use of two salivary cortisol samples, measured 1 hour and 30 minutes 290 
after cortisone acetate, as an indication of 24-hour cortisol exposure has been suggested but 291 
this does not give an indication of fluctuating changes (27). The use of multiple salivary 292 
cortisone samples allows an objective assessment of cortisol exposure after hydrocortisone 293 
and has been used during hydrocortisone infusion (28). Moreover, measuring salivary 294 
cortisone after hydrocortisone does not have the same risk for drug contamination as 295 
observed when measuring salivary cortisol in this setting (29). As a wide variability in 296 
hydrocortisone pharmacokinetics and glucocorticoid sensitivity exists between individuals 297 
multiple salivary cortisone sampling can be used in assessing hydrocortisone replacement. 298 
Interestingly early morning salivary cortisone has been proposed to be a superior test to 299 
salivary cortisol in detecting severe adrenal insufficiency in patients on glucocorticoids (30).  300 
 301 
Our study is limited by the relatively small number of subjects and its cross-sectional nature 302 
but the analysis was carried out in detail, under carefully controlled environmental conditions 303 
with strict supervised sampling of multiple samples and we have undertaken a detailed 304 
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analysis. Furthermore the study is only carried out in men. It has been shown that in women 305 
on oestrogens besides a rise in the bound cortisol pool, free cortisol pharmacokinetics may be 306 
affected resulting in excess cortisol exposure especially in patients on hydrocortisone in 307 
whom the HPA axis might not adjust (7). Salivary cortisone reflects free cortisol 308 
concentrations irrespective of elevations in CBG (14) but detailed modelling of the 309 
mathematical relationship with total circulating cortisol levels in this setting has not been 310 
performed. Salivary cortisone has been shown to be a more useful tool to assess the cortisol 311 
circadian rhythm under both physiological conditions and after oral hydrocortisone 312 
replacement. We have shown how normative salivary cortisone levels can be calculated and 313 
displayed. Future studies should assess salivary cortisone measurement prospectively in 314 
clinical and research settings to evaluate salivary cortisone use as a diagnostic tool.   315 
  316 
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Tables 
Table 1 Time and concentration taken from best fit individual cosinor models (likelihood 
ratio test P<=0.001) in 14 healthy male volunteers. 
 Clock time  
Median (range) 
Concentration 
Median (range) 
Peak:trough ratio 
Median (range) 
Variable  Acrophase Nadir Peak Trough  
Cortisol1   
(nmol/L) 
07:24  
(06:48-08:08) 
23:23  
(22:43-00:03) 
323.9  
(289.0-443.9) 
30.7  
(5.0-67.6) 
11.05  
(6.57-66.77) 
Cortisone1 
(nmol/L) 
07:31  
(06:48-08:51) 
23:05  
(22:36-00:24) 
64.8  
(44.4-86.1) 
10.2  
(3.7-22.7) 
6.16  
(3.37-15.24) 
FCI1 
(nmol/mg) 
 
07:24  
(06:41-08:08) 
23:08  
(22:29-23:55) 
15.5  
(14.9-18.4) 
1.16 
(0.38-3.36) 
12.86  
(5.46-40.67) 
CBG2 
(mg/L) 
16:52  
(16:12-17:32) 
04:49  
(04:16-05:28) 
23.2  
(19.4-27.2) 
20.8  
(17.1-24.7) 
1.12  
(1.10-1.14) 
Albumin2 
(g/L) 
14:27  
(13:40-14:52) 
02:38  
(01:44-03:18) 
46.1  
(42.7-48.5) 
42.3  
(38.9-44.7) 
1.09  
(1.09-1.10) 
1 Two-harmonic model is best fit (P 
2 One-harmonic model is best fit (P 
FCI: Free Cortisol Index, CBG: Cortisol Binding Globulin 
 
 
 
  
7DEOHV &OLFNKHUHWRGRZQORDG7DEOH7DEOHV6DOLYDU\FRUWLVRQHPDQXVFULSWY9ILQDOGRF[
Table 2 &RUUHODWLRQ PDWUL[ 3HULRG  ZLWK VLJQLILFDQW FRUUHODWLRQ FRHIILFLHQW ȡ P<=0.001) 
(N=14)    
           ȇ 
(95% CI) 
 
Serum 
F 
Serum 
E 
FCI Free 
F1 
Salivary 
F2 
Salivary 
E 
Serum F 1 0.83 
(0.79-
0.86) 
0.97 
(0.96-
0.98) 
0.91 
(0.83-
0.96) 
0.90 
(0.87-
0.92) 
0.91 
(0.89-
0.93) 
Serum E  1 0.81 
(0.78-
0.85) 
0.72 
(0.50-
0.86) 
0.52 
(0.40-
0.61) 
0.77 
(0.71-
0.81) 
FCI   1 0.90 
(0.80-
0.95) 
0.90 
(0.87-
0.92) 
0.96 
(0.95-
0.97) 
Free F1    1 0.89 
(0.76-
0.95) 
0.85 
(0.72-
0.93) 
Salivary F2     1 0.87 
(0.83-
0.90) 
Salivary E      1 
1
 Undetectable values excluded (6% values) 
2 Undetectable values excluded (19% values) 
 F: cortisol, E: cortisone, FCI: Free Cortisol Index 
 
  
Table 3a Correlation matrix Period 2 after oral HC with ȡ (P<=0.001) (N=14) 
           ȡ  
(95% CI) 
 
Serum 
F 
Serum 
E 
FCI Salivary 
F1 
Salivary 
E 
Serum F 1.0 0.51 
(0.40-
0.60) 
0.97 
(0.96-
0.97) 
0.30 
(0.16-
0.43) 
0.84 
(0.79-
0.87) 
Serum E  1.0 0.53 
(0.43-
0.62) 
NS 0.61 
(0.52-
0.68) 
FCI   1.0 0.30 
(0.16-
0.43) 
0.88 
(0.84-
0.90) 
Salivary F1    1.0 NS 
Salivary E     1.0 
NS ³QRWVLJQLILFDQWS! 
1
 Undetectable values excluded (19%) 
Table 3b Correlation matrix PHULRGDIWHULQWUDYHQRXV+&ZLWKȡP<=0.001)  
        ȡ 
(95% CI) 
Serum 
F 
Serum 
E 
FCI Salivary 
F1 
Salivary 
E 
Serum F 1.0 0.68 
(0.6-
0.75) 
0.97 
(0.97-
0.98) 
0.89 
(0.85-
0.91) 
0.94 
(0.92-
0.95) 
Serum E  1.0 0.68 
(0.60-
0.74) 
0.33 
(0.20-
0.46) 
0.66 
(0.58-
0.73) 
FCI   1.0 0.87 
(0.84-
0.91) 
0.96 
(0.95-
0.97) 
Salivary F1    1.0 0.87 
(0.83-
0.90) 
Salivary E     1.0 
1
 Undetectable values excluded (19%) 
F:cortisol, E:cortisone, FCI: Free Cortisol Index 
 
 
Figure 1: Cosinor models for serum cortisol, cortisone, Free Cortisol Index (FCI), 
Cortisol Binding Globulin (CBG) and albumin along with their corresponding 95% 
prediction intervals overlaid on observed data (+) (N=14). The number of harmonics 
for the models was 2 for cortisol, cortisone and FCI and 1 for albumin and CBG. 
 
  
)LJXUHV &OLFNKHUHWRGRZQORDG)LJXUH)LJXUHV6DOLYDU\FRUWLVRQHPDQXVFULSWY5HYLVHGYILQDOGRF[
 Figure 2: (a) Scatter graph showing relation of serum cortisol to salivary cortisone by 
Period. (b) Mixed-effects model showing per subject variation. The lines are the 
individual subject regression lines and all have the same slope with minor variation in 
intercept. The fixed effects line is shown in cyan. 
 
  
Figure 3: Concentration-time profiles for salivary cortisol (a) and salivary cortisone 
(b) including 2-cosinor fixed-effects models and their corresponding 95% prediction 
LQWHUYDOV 7KHVH ZHUH REWDLQHG YLD ³EDFN WUDQVIRUPDWLRQ´ XVLQJ WKH IL[HG HIIHFWV
components of their respective regression models. Salivary cortisone values between 
2300h and 0600h were predicted by inverting the mixed effects model and applying it 
to the night-time serum cortisol observations. By cosinor analysis the median (range) 
was estimated as (a) salivary cortisol acrophase 07:24 (06:48 ± 08:08), nadir 23:23 
(22:43 ± 00:03), peak 8.3nmol/L (6.6 - 15.5nmol/L), trough 0.1nmol/L (0.0 - 
0.4nmol/L) and peak:trough ratio 122.8 (43.3 ± 4505.0), and (b) salivary cortisone 
acrophase 07:24 (06:48 ± 08:08, nadir 23:23 (22:43 ± 00:03), peak 27.1nmol/L (18.0 
± 45.1nmol/L), trough 1.8nmol/L (0.3 ± 5.0nmol/L) and peak:trough ratio 14.8 (8.3 ± 
111.6). 
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